Navigation Links
Palatin Technologies Announces Halting of Phase I Clinical Trial of Obesity Compound in AstraZeneca Research Collaboration
Date:6/19/2012

CRANBURY, N.J., June 19, 2012 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN) today announced that a Phase I clinical trial being conducted by AstraZeneca of AZD2820, a subcutaneously-administered peptide melanocortin-4 receptor partial agonist under development for the treatment of obesity, has been halted. AZD2820 is a clinical candidate under development by AstraZeneca from a collaborative research program with Palatin Technologies.

The Phase 1 clinical trial of AZD2820 was halted by the Safety Review Committee established by AstraZeneca after meeting a predefined stopping criterion. The stopping criterion was a serious adverse event. It is suspected that the subject may have had an allergic reaction following his first dose. The subject was treated at the clinical site and has fully recovered. A review and investigation of the incident has commenced.

"We are pleased that the subject has fully recovered from this unfortunate adverse event and we will work closely with our partner AstraZeneca to investigate the cause of this incident and the overall plans for the AZD2820 program," said Dr. Carl Spana, President and Chief Executive Officer of Palatin. "AstraZeneca has confirmed their remaining commitment to the continued advancement of melanocortin agonists for treatment of obesity, including a number of collaboration compounds in various stages of preclinical testing."

The phase I single center study, conducted by AstraZeneca, targeted enrolling 72 obese but otherwise healthy male subjects, with a body mass index between 30 and 35 kg/m2, in a randomized, single-blind, placebo-controlled, trial. Eleven subjects had completed their dosing regimen prior to the halting of the trial. The primary outcome of the study is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD2820 after administration of multiple ascending doses. Another Phase 1 single ascending dose study of AZD2820 was finalize
'/>"/>

SOURCE Palatin Technologies, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on May 14, 2012
2. Palatin Technologies, Inc. To Report Fiscal Year 2012 Third Quarter Results; Teleconference and Webcast to be held on May 14, 2012
3. Palatin Technologies, Inc. to Present at the 24th Annual ROTH OC Growth Stock Conference
4. Palatin Technologies to Present at Windhovers Therapeutic Area Partnerships Conference
5. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
6. Palatin Technologies, Inc. to Report Fiscal Year 2012 First Quarter Results; Teleconference and Webcast to be held on November 15, 2011
7. Althea Technologies Appoints Dr. Dennis Fenton As Chairman Of Its Scientific Advisory Board
8. ATCC Announces Agreement with Life Technologies Corporation to Sell and Distribute Green Fluorescent Protein (GFP)-based Materials
9. Life Technologies Signs Licensing Agreement with iPS Academia Japan for Global Patent Portfolio Rights to Induced Pluripotent Stem Cell Technology
10. OrthoAccel Technologies, Inc. Names U.S. National Sales Director
11. Metamaterials, quantum dots show promise for new technologies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... 2014 Research and Markets ... "Spectroscopy Equipment and Accessories - Global ... offering. This report analyzes ... Accessories in US$ Thousands by the following ... Spectrometers, NMR-EPR Spectrometers, Near Infrared (NIR) Spectrometers, ...
(Date:8/19/2014)... , Aug. 19, 2014 /PRNewswire/ - iCo Therapeutics Inc. ... today reported results of its Oral Amphotericin B ... reservoirs.  The study, conducted by ImmuneCarta®, the immune ... vitro effectiveness of Oral Amp B in ... in individuals despite intensive treatment with antiretroviral therapy. ...
(Date:8/18/2014)... 18, 2014 /PRNewswire/ - SQI Diagnostics Inc. (TSX-V: SQD), a ... and products for advanced microarray diagnostics, today announced it ... 22 at 2:00 pm ET.  During ... a brief review of SQI,s recent commercialization progress and ... industry veteran recently appointed to the Board of Directors ...
(Date:8/18/2014)... Global HIV Infection Drug Market and Pipeline Insight is ... HIV infection and the number of deaths due to AIDS ... across the globe. It has been estimated that the death ... 2013, with the rates for children being even much lower. ... rates has been the improved access to antiretroviral drugs and ...
Breaking Biology Technology:Global Spectroscopy Equipment and Accessories - Strategic Business Report 2014 2iCo Therapeutics Announces Positive Oral Amphotericin B Study Results 2iCo Therapeutics Announces Positive Oral Amphotericin B Study Results 3SQI Diagnostics Announces Investor Conference Call with Dr. Allan Pronovost 2SQI Diagnostics Announces Investor Conference Call with Dr. Allan Pronovost 3Global HIV Infection Drug Market Overview 2Global HIV Infection Drug Market Overview 3Global HIV Infection Drug Market Overview 4
... billions of clot-forming platelets every day, but there are ... with certain diseases or during invasive surgery. Now, University ... can induce bone marrow cells called megakaryocytes to quadruple ... a graduate student of pharmacology in Penn,s Perelman School ...
... Tiny chemical particles emitted by diesel exhaust fumes could raise ... have found that ultrafine particles produced when diesel burns are ... blood clots forming in arteries, leading to a heart attack ... measured the impact of diesel exhaust fumes on healthy volunteers ...
... Mass. -- A novel application of carbon nanotubes, developed by ... solar energy for use whenever it,s needed. Storing the ... to electricity or storing the heat itself in a heavily ... chemical material can be stored for long periods of time ...
Cached Biology Technology:Penn researchers show single drug and soft environment can increase platelet production 2Penn researchers show single drug and soft environment can increase platelet production 3Diesel fumes pose risk to heart as well as lungs, study shows 2MIT research update: New way to store sun's heat 2MIT research update: New way to store sun's heat 3
(Date:8/19/2014)... . Wind ... large amount of electricity is to be produced with renewable ... be stored during productive periods so that these fluctuations can ... adequate for the purpose. Science and industry are therefore working ... systems that used to be too expensive or unsophisticated to ...
(Date:8/19/2014)... not a monkey. It,s not a lemur. It,s not an ... Philippine tarsier: a tiny, adorable and downright "cool" primate from ... Americans are familiar with," said Rafe Brown, curator-in-charge at the ... and ears; an extremely cute, furry body; a long tail ... fingers and toe tips that look a bit like the ...
(Date:8/19/2014)... retail seafood counters in 10 different states show ... to unexpectedly high levels of mercury, a harmful ... fish of the same species, but from a ... according to new research by University of Hawai,i ... is essential to allow consumers to choose sustainable ...
Breaking Biology News(10 mins):Asian inventions dominate energy storage systems 2Asian inventions dominate energy storage systems 3Philippine tarsier gets boost from Kansas research, and genetic proof of a new variety 2Philippine tarsier gets boost from Kansas research, and genetic proof of a new variety 3Seafood substitutions can expose consumers to unexpectedly high mercury 2Seafood substitutions can expose consumers to unexpectedly high mercury 3
... as 25 percent of hospital nurses go without sleep for ... on the night shift, which is the least effective strategy ... That is one of the results of the first study ... between day and night sleep cycles. The study was based ...
... hydrogen in a sustainable way is a challenge and production ... Xile Hu has discovered that a molybdenum based catalyst is ... the research are published online in Chemical Science ... this discovery has just been filled. Existing in large quantities ...
... Ceelox, Inc. (OTCBB: CELO) announced today that the ... cloud applications using biometrics. Ceelox ID Online® utilizes a ... Internet server-based biometric software application. This enables users to ... i.e. user name and password, compromised or stolen by ...
Cached Biology News:A sleep strategy commonly used by night nurses throws off their circadian clocks 2A sleep strategy commonly used by night nurses throws off their circadian clocks 3Ceelox Provides Biometric Identity Access to Cloud Applications 2Ceelox Provides Biometric Identity Access to Cloud Applications 3